Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey

Digital Transformation in Pharma Manufacturing: Industry Perspectives Survey

The bio/pharmaceutical manufacturing and development industry is at a critical turning point (1-8). As new modalities move toward commercialization, traditional manufacturing approaches are under intense pressure (5,7-12). At the same time, such technologies as automation, advanced analytics, digital twins, and artificial intelligence are rapidly evolving and promising to transform how medicines are developed, produced, and delivered.

Yet adoption has been uneven. While some organizations are piloting cutting-edge digital tools across their operations, others are still navigating legacy systems, limited resources, or regulatory uncertainty (2-6,10,11,13-18). And even for those further along in the journey, questions remain about integration, workforce readiness, cost, and ultimately, the measurable impact on efficiency, quality, and speed to market (1,2,7,9-12,19-23).

That’s why we’re focusing this survey on digital transformation and technology adoption. We want to understand where the industry truly stands today, what barriers professionals are facing, and what opportunities are most within reach. Your perspective—whether from development, manufacturing, quality, engineering, or regulatory—will help build a clearer picture of the challenges and successes shaping digital change.

By sharing your experiences, you’ll help highlight what’s working, where support is needed, and how the industry can collectively move forward. The insights gathered will inform a broader discussion within the community and provide valuable benchmarks for organizations navigating their own transformation.

Your voice is essential to capturing this moment in the industry’s evolution. We appreciate your time and perspective, and we look forward to sharing the results with you and your peers.

CLICK HERE TO COMPLETE THE SURVEY

References

1. Cole, C. The Importance for CDMOs of Partnering With a Sponsor’s Mindset. PharmTech.com. August 13, 2025.
2. Mirasol, F. How Rare Diseases Shape Drug Manufacturing and Development Innovation (Part 1). BioPharmInternational.com. August 14, 2025.
3. Lavery, P. MHRA Approves Sanofi’s Teplizumab to Delay Onset of Stage III T1D. BioPharmInternational.com. August 14, 2025.
4. Cole, C. Biopharma Development Hurdles: Lessons from Vedanta’s Live Bacteria Cocktail Failure. BioPharmInternational.com. August 14, 2025.
5. Cole, C. Sustainability Becomes Essential: Green Manufacturing and Supply Chain Resilience in Bio/Pharma. PharmTech.com. August 15, 2025.
6. Lavery, P. FDA Approves Precigen’s Immunotherapy to Treat Recurrent Respiratory Papillomatosis. BioPharmInternational.com. August 15, 2025.
7. Cole, C. Onshoring’s Unexpected Benefits: Quality, Efficiency, and Supply Chain Resilience. PharmTech.com. August 14, 2025.
8. Mirasol, F. EMA Grants Orphan Designation to Rilzabrutinib for IgG4-Related Disease. PharmTech.com. August 15, 2025.
9. Mirasol, F. ElevateBio BaseCamp Achieves First Multi-Modality ICMC Certification in Commercial CGT Manufacturing. BioPharmInternational.com. August 14, 2025.
10. Mirasol, F. ProBio Launches End-to-End AAV Production at NJ Manufacturing Site. BioPharmInternational.com. August 13, 2025.
11. Mirasol, F. Strand’s Programmable mRNA Pipeline Advances on $153 Million in New Funding. BioPharmInternational.com. August 12, 2025.
12. Lavery, P. After mRNA Rollback, BARDA Pulls Plug on Vaxart Oral COVID Vaccine Trial. BioPharmInternational.com. August 12, 2025.
13. Mirasol, F. Merck and Daiichi Sankyo’s I-DXd Earns FDA Breakthrough Therapy Status in Small Cell Lung. BioPharmInternational.com. August 19, 2025.
14. Mirasol, F. FDA Grants Breakthrough Therapy Designation to Bispecific ADC for EGFR-Mutant Lung Cancer. BioPharmInternational.com. August 18, 2025.
15. Haigney, S. FDA Releases Guidance on Oncology Therapeutic Radiopharmaceuticals. PharmTech.com. August 19, 2025.
16. Haigney, S. Telstar to Showcase Integrated GMP Services at Farmaforum. PharmTech.com. August 18, 2025.
17. Haigney, S. The Impact of Reclassifying 7-OH Products. PharmTech.com. August 19, 2025.
18. Haigney, S. Kratom and the Impact of 7-OH Reclassification. PharmTech.com. August 18, 2025.
19. Haigney, S. FDA Commissioner Applauds Florida Restriction on 7-OH Opioids. PharmTech.com. August 14, 2025.
20. Lavery, P. Lilly Statement: MFN Pricing Targeted for September 1, Pushback on Pharma Tariffs. BioPharmInternational.com. August 18, 2025.
21. Cole, C. Intellectual Property as a Core Strategy in Drug Formulation and Development. BioPharmInternational.com. August 18, 2025.
22. Lavery, P. Iterum's UTI Drug Launches as First Commercial Oral Penem Antibiotic in US. PharmTech.com. August 20, 2025.
23. Cole, C. Bio/Pharma's Tariff Response: Key Insights from Industry Survey Results. PharmTech.com. August 20, 2025.